Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Drugmaker Eli Lilly presented trial results to medical professionals on Saturday showing its next-generation obesity drug retatrutide curbed sleep apnea severity in addition to boosting weight loss and helping knee pain.

In a Phase 3 trial, Lilly ‌found a ⁠weekly ⁠injection of retatrutide reduced moderate-to-severe obstructive sleep apnea severity by 60.6% in adults with obesity. Lilly's older drug Zepbound is approved for the condition.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.